secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001193125-23-188930
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma rejects activist consent solicitation to remove board without cause under Delaware law
--------------------------------------------------------------------------------

- Anson Advisors and Cable Car Capital launched consent solicitation on July 17, 2023 to remove all directors without cause and repeal recent bylaw amendments.
- MEI states removal proposal is invalid under Delaware law because classified board directors may only be removed for cause; charter does not provide otherwise.
- Bylaw proposal is unnecessary as no bylaw amendments have been made since February 23, 2023, and board has no current intent to amend.
- Board urges shareholders to vote FOR the pending Infinity Pharmaceuticals merger, endorsed by ISS and Glass Lewis.
- Company reserves the right to contest any solicitation or actions taken in connection with the invalid proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523188930/0001193125-23-188930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523188930/d531811d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-188930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer